Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Mesenchymal Cells for Rotator Cuff Repair
NCT03838666Phase 2Terminated
- Sponsor
- Bioinova
- Start
- Dec 2012
- Primary completion
- Nov 2015
- Modality
- Stem Cell Therapies
01
Overview
Phase 2, open-label, single-arm trial of autologous mesenchymal stem cells in rotator cuff tear, sponsored by Bioinova. Primary endpoints: Occurrence of adverse events of treatment by hAMSC - systemic reactions at 1 year and Occurrence of adverse events of treatment by autologous mesenchymal stem cells - local reactions at 1 year. Started Dec 2012; status: terminated.
02
Drugs
autologous mesenchymal stem cells
03
Conditions
rotator cuff tear
Beyond the preview
Go deeper on NCT03838666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03838666.